TUMOR CELL PANEL WITH CHARACTERIZED EXPRESSION OF PD-L1 FOR PRECLINICAL STUDIES OF ANTICANCER DRUGS AND IMMUNE CHECKPOINT INHIBITORS INTERACTION

Abstract

PD-L1 (Programmed death-ligand 1), a membrane protein of the immunoglobulin superfamily, is one of the targets for cancer immunotherapy. A panel of 14 cancer cell cultures with different constitutive PD-L1 expression level was formed and characterized. The panel is recommended for preclinical studies of a cytostatic drug effect on PD-L1 expression and for predicting the ef cacy of their combination with immune checkpoint inhibitors.